SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
RCKT reported Third Quarter 2026 results. The price and volatility reaction is pending.
RCKTearnings

Earnings reactions, page 3

Rocket Pharmaceuticals, Inc. (RCKT) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $31.2 million for the three months ended September 30, 2026, compared to $34.1 million for the three months ended September 30, 2025.
  • General and administrative expenses were $19.8 million for the three months ended September 30, 2026, compared to $18.4 million for the three months ended September 30, 2025.
  • Net loss was $49.2 million, or $0.43 per share (basic and diluted), for the three months ended September 30, 2026, compared to $50.3 million, or $0.45 per share (basic and diluted), for the three months ended September 30, 2025.
  • Other Income was $1.8 million for the three months ended September 30, 2026, compared to $1.9 million for the three months ended September 30, 2025.
  • Cash, cash equivalents and investments were $279.4 million as of September 30, 2026.

Guidance

  • Rocket expects its cash, cash equivalents and investments as of September 30, 2026, to fund planned operations into Q3 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →